Is the 10% pharmacy funding uplift enough?

What did the 2026/27 deal add?

The deal added £340m, taking Community Pharmacy Contractual Framework (CPCF) funding in England to £3.636bn for 2026/27. The Department of Health and Social Care (DHSC) calls that a 10.3% rise. It was agreed with NHS England and Community Pharmacy England (CPE) on 29 May 2026, eight weeks into the financial year.

The money arrives through a small number of lines. The single activity fee rises 6p to £1.52 an item, backdated to May. Allowed medicines margin rises by £200m to £1.1bn. Up to £239m of past margin over-delivery is written off instead of being recovered through lower Category M prices. A new NHS independent prescribing service starts in the autumn with a £500 set-up fee and £525 a month. Nothing else changes. The table summarises the headline figures from the settlement document; for the line-by-line detail, see what the 2026/27 pharmacy contract actually pays.

CPE's committee voted to accept. Its chief executive, Janet Morrison, said accepting the deal "does not mean we think it is enough - for this year or the future". Refusing it, she said, would have put more pharmacies at greater risk. That is a negotiator describing a floor, not a settlement. The question is how far above the floor the sector now stands.

Is funding back to its 2015 level?

No. DHSC's own figures show that funding is still well short of its 2015/16 value, even after two large rises. On 24 February 2026 the pharmacy minister, Stephen Kinnock, answered a written question from Helen Morgan MP with a year-by-year table. It converts every year's cash funding into 2025/26 prices using the GDP deflator.

Read across the bottom rows. Funding was frozen at £2,592m for seven years while prices rose. By 2023/24 its real value was £2,776m, 28% below 2015/16. The 2025/26 rise recovered part of that. It still left funding £791m below 2015/16 in real terms, the figure the Company Chemists' Association rounded to £800m. The table excludes Pharmacy First and the vaccination fees, which DHSC notes were funded on top.

Now place 2026/27 against it. The new total is £3,636m in cash, and it includes Pharmacy First. That is £228m below what the 2015/16 settlement was worth in 2025/26 prices, before you deflate 2026/27 for another year of inflation. By coincidence it is exactly the real value of 2016/17 funding, the year of the cuts. On this yardstick the uplift closes most of the decade's gap, but not all of it, and it does so partly by counting a service that did not exist in 2015.

Margin tells the same story. A second written answer, reported by The Pharmacist on 11 March 2026, put retained margin at £1.02bn in 2015/16 and £900m in 2025/26 in real terms, a fall of £120m. The £1.1bn allowed for 2026/27 recovers that, in cash at least.

How much do this year's cost rises take back?

Most of it, on the sector's own arithmetic, but not quite all. In December 2025 the National Pharmacy Association (NPA) estimated that pharmacies in England faced £275m of additional costs in 2026. At least £159m of that came from wages and inflation, and at least £104m from rising prescription volumes. It said an 8.9% uplift would only stand still. Its chair, Dr Olivier Picard, repeated in May that "anything less than an 8.9% uplift would be a pay cut".

The deal delivered 10.3%. The two figures are not on identical bases, because DHSC's percentage includes Pharmacy First and the NPA's did not. But the order of magnitude holds. Set £340m against £275m and the sector clears its own standstill line by about £65m. Spread across 9,940 pharmacies, that is roughly £6,500 each. That is our arithmetic, not anyone's official estimate, and it is the most generous reading available.

The cost pressures are not hypothetical. The National Living Wage rose from £12.21 to £12.71 an hour on 1 April 2026, a 4.1% increase on the largest line in most pharmacy accounts. Picard described his own wage bill rising 6.9% and his business rates going from about £10,000 to about £18,000. For how the rates changes land on pharmacies, see how business rates work for pharmacies in 2026. And medicines keep costing more than the Drug Tariff pays: Picard counted 95 price concessions in March 2025 and 216 a year later, while CPE's tracker showed 223 for August 2026.

The Independent Pharmacies Association takes a harder line. It calculates that a pharmacy dispensing 10,000 items a month needed more than £65,000 of extra funding to keep pace with inflation and received about £9,500 from this deal. Its chief executive, Dr Leyla Hannbeck, said the settlement "leaves an average pharmacy branch facing a nearly sixty thousand pounds annual shortfall". The gap between the NPA and IPA figures is mostly a matter of what you count as a cost and over what period. Both agree the uplift is absorbed quickly.

What does the service actually cost to run?

About £5bn a year in 2023/24, according to the only independent estimate, against £2.755bn of funding that year. The analysis was commissioned by DHSC and NHS England from Frontier Economics and IQVIA and published in October 2024. CPE summarised it for MPs in March 2025. Its central finding was a full economic cost of £5.063bn for NHS pharmaceutical services in England, leaving a shortfall of £2.308bn.

Full economic cost is a demanding measure. It includes a normal return on capital and the cost of everything a pharmacy does for the NHS, paid or not. Nobody expects the contract to reach it in one year. But it is the only published number for what the service costs, and it was produced for the government, not by the trade bodies. On this yardstick, £3.636bn is still about £1.4bn short of a cost base measured three years ago and rising since.

Will pharmacies keep closing?

Probably, though more slowly than in the worst years. The network has been shrinking for a decade. Analysis of NHSBSA data for Pharmacy Business shows 9,944 community pharmacies in England in March 2026 and 9,940 in April, against a 2015 peak of 11,949. That is 2,009 fewer premises. Between January 2024 and March 2025 alone, England recorded 274 closures.

The shape of the network has changed as much as its size. Small independents of one to five outlets numbered 5,067 in April 2026, 51% of the total, while groups of 100 or more had fallen to 3,167. Most of the big-chain disposals have already happened. What remains is a network of small owners with less balance-sheet cushion than the chains they replaced. For the pattern by region and ownership, see how many UK pharmacies are closing, and where.

A 6p fee rise changes the outlook for a pharmacy that was close to breaking even. It does not change the outlook for one already losing money on 47% of the sector's own numbers. The IPA said in May that closures would continue; the NPA said the uplift would be "mostly eaten up" by costs. Neither had an incentive to say otherwise, but neither had to invent the trend.

What does the uplift fix?

It fixes cash flow, clawback risk and a thin year for margin, and it opens one new income line. Those are real gains and it is worth being specific about them.

The first two items are the ones an accountant would notice. The backdated fee is real money in the bank. The write-off removes a liability that would have been taken back through the Drug Tariff over the following year. For a business on tight cash, both matter more than the headline percentage.

What does it leave untouched?

It leaves the reimbursement model, the pattern of dispensing at a loss and the question of what happens after March 2027. All three were pushed into a joint reform programme rather than settled.

Dispensing at a loss is the clearest example. The deal changed no reimbursement rule. A pharmacy that pays more than the Drug Tariff price for a medicine still earns the same £1.52 fee and still takes the loss unless a concession is granted in time. The settlement document acknowledges "concerns around the distribution of medicine margin across the supply chain" and promises to keep working with CPE. It commits to no mechanism. See how price concessions work and why pharmacies dispense at a loss for the detail.

Meanwhile DHSC has pressed on with reimbursement changes of its own. Category H, a new Drug Tariff category for multi-source products, started in March 2026 with prices set from suppliers' actual sales data. CPE objected and said DHSC was "imposing these changes". Whether that counts as reform or as the problem depends on your buying terms.

The Pharmacy Access Scheme is retained at £20m, with a review promised and any changes from 2027/28. There is no multi-year funding path; the deal covers one year and the 2027/28 negotiation starts from scratch. CPE's briefing says the reform programme will "inform future strategy for community pharmacy and input to the next contractual negotiations and beyond". Neither the settlement document nor the briefing sets out workstreams, membership or a timetable. For what is known, see what the community pharmacy reform programme will change.

So is it enough?

It depends which question you are asking, and the honest answer is different for each. Enough to stand still against 2026 cost rises: yes, narrowly, on the NPA's own figures. Enough to restore the real value of 2015 funding: no, by about £230m before inflation, and only by counting Pharmacy First. Enough to cover what the service costs to run: no, by more than a billion pounds on the government's own commissioned analysis.

The fair verdict is the one CPE gave: significant, and not enough. The uplift stops the sector sliding further and buys a year in which the reform programme can either produce a new model or fail to. Judged against the last decade, it is the second large rise in a row after seven years of freezes. Judged against the cost of the service it funds, it is a down payment. For the year ahead, see what is coming for UK pharmacy in 2027.

Key takeaways

FAQs